228 related articles for article (PubMed ID: 15938034)
1. Prevention and treatment of diabetic nephropathy: the program for irbesartan mortality and morbidity evaluation.
Ravera M; Ratto E; Vettoretti S; Parodi D; Deferrari G
J Am Soc Nephrol; 2005 Mar; 16 Suppl 1():S48-52. PubMed ID: 15938034
[TBL] [Abstract][Full Text] [Related]
2. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
Lewis EJ; Lewis JB
Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
[TBL] [Abstract][Full Text] [Related]
3. Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
Ruilope LM; Segura J
Clin Ther; 2003 Dec; 25(12):3044-64. PubMed ID: 14749145
[TBL] [Abstract][Full Text] [Related]
4. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.
Croom KF; Curran MP; Goa KL; Perry CM
Drugs; 2004; 64(9):999-1028. PubMed ID: 15101793
[TBL] [Abstract][Full Text] [Related]
5. The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
Zanella MT; Ribeiro AB
Clin Ther; 2002 Jul; 24(7):1019-34. PubMed ID: 12182249
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
Berl T; Hunsicker LG; Lewis JB; Pfeffer MA; Porush JG; Rouleau JL; Drury PL; Esmatjes E; Hricik D; Parikh CR; Raz I; Vanhille P; Wiegmann TB; Wolfe BM; Locatelli F; Goldhaber SZ; Lewis EJ;
Ann Intern Med; 2003 Apr; 138(7):542-9. PubMed ID: 12667024
[TBL] [Abstract][Full Text] [Related]
7. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.
Rodby RA; Rohde RD; Clarke WR; Hunsicker LG; Anzalone DA; Atkins RC; Ritz E; Lewis EJ
Nephrol Dial Transplant; 2000 Apr; 15(4):487-97. PubMed ID: 10727543
[TBL] [Abstract][Full Text] [Related]
8. A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.
Palmer AJ; Valentine WJ; Tucker DM; Ray JA; Roze S; Annemans L; Lapuerta P; Chen R; Gabriel S; Carita P; Rodby RA; de Zeeuw D; Parving HH; Laville M
Curr Med Res Opin; 2006 Nov; 22(11):2095-100. PubMed ID: 17076969
[TBL] [Abstract][Full Text] [Related]
9. Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.
Palmer AJ; Valentine WJ; Ray JA
Int J Clin Pract; 2007 Oct; 61(10):1626-33. PubMed ID: 17877649
[TBL] [Abstract][Full Text] [Related]
10. An update of irbesartan and renin-angiotensin system blockade in diabetic nephropathy.
García-Donaire JA; Segura J; Ruilope LM
Expert Opin Pharmacother; 2005 Aug; 6(9):1587-96. PubMed ID: 16086646
[TBL] [Abstract][Full Text] [Related]
11. Renal and cardiovascular protection in type 2 diabetes mellitus: angiotensin II receptor blockers.
Deferrari G; Ravera M; Deferrari L; Vettoretti S; Ratto E; Parodi D
J Am Soc Nephrol; 2002 Nov; 13 Suppl 3():S224-9. PubMed ID: 12466318
[TBL] [Abstract][Full Text] [Related]
12. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings.
Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; Cordonnier DJ
Nephrol Dial Transplant; 2003 Oct; 18(10):2059-66. PubMed ID: 13679481
[TBL] [Abstract][Full Text] [Related]
13. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.
Pohl MA; Blumenthal S; Cordonnier DJ; De Alvaro F; Deferrari G; Eisner G; Esmatjes E; Gilbert RE; Hunsicker LG; de Faria JB; Mangili R; Moore J; Reisin E; Ritz E; Schernthaner G; Spitalewitz S; Tindall H; Rodby RA; Lewis EJ
J Am Soc Nephrol; 2005 Oct; 16(10):3027-37. PubMed ID: 16120823
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective.
Coyle D; Rodby R; Soroka S; Levin A; Muirhead N; de Cotret PR; Chen R; Palmer A
Clin Ther; 2007 Jul; 29(7):1508-23. PubMed ID: 17825702
[TBL] [Abstract][Full Text] [Related]
15. [Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy].
Palmer AJ; Roze S; Rodby RA; Valentine WJ; Ritz E; Lehnert H
Dtsch Med Wochenschr; 2006 Aug; 131(31-32):1721-6. PubMed ID: 16868875
[TBL] [Abstract][Full Text] [Related]
16. A clinical trial in type 2 diabetic nephropathy.
Lewis EJ; Hunsicker LG; Rodby RA;
Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S191-4. PubMed ID: 11576953
[TBL] [Abstract][Full Text] [Related]
17. Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial.
Evans M; Bain SC; Hogan S; Bilous RW;
Nephrol Dial Transplant; 2012 Jun; 27(6):2255-63. PubMed ID: 22172728
[TBL] [Abstract][Full Text] [Related]
18. The value of irbesartan in the management of hypertension.
Bramlage P; Durand-Zaleski I; Desai N; Pirk O; Hacker C
Expert Opin Pharmacother; 2009 Aug; 10(11):1817-31. PubMed ID: 19601700
[TBL] [Abstract][Full Text] [Related]
19. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Lewis EJ; Hunsicker LG; Clarke WR; Berl T; Pohl MA; Lewis JB; Ritz E; Atkins RC; Rohde R; Raz I;
N Engl J Med; 2001 Sep; 345(12):851-60. PubMed ID: 11565517
[TBL] [Abstract][Full Text] [Related]
20. What is the impact of PRIME on real-life diabetic nephropathy?
Ruilope LM
Int J Clin Pract; 2004 Mar; 58(3):268-76. PubMed ID: 15117095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
